Trial Profile
A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms NALIRICC
- 13 Sep 2022 Primary endpoint (progression-free survival) has not been met according to the results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results assessing the c the efficacy of pegylated liposomal irinotecan formulation (nal-IRI)/5-FU/leucovorin (LV) compared to 5-FU/LV in second line advanced biliary tract cancer presented at the 47th European Society for Medical Oncology Congress
- 17 May 2022 Status changed from recruiting to completed.